BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 14742312)

  • 1. Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma.
    Belinsky SA; Klinge DM; Liechty KC; March TH; Kang T; Gilliland FD; Sotnic N; Adamova G; Rusinova G; Telnov V
    Carcinogenesis; 2004 Jun; 25(6):1063-7. PubMed ID: 14742312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers.
    Belinsky SA; Palmisano WA; Gilliland FD; Crooks LA; Divine KK; Winters SA; Grimes MJ; Harms HJ; Tellez CS; Smith TM; Moots PP; Lechner JF; Stidley CA; Crowell RE
    Cancer Res; 2002 Apr; 62(8):2370-7. PubMed ID: 11956099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
    Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
    Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression.
    Pulling LC; Divine KK; Klinge DM; Gilliland FD; Kang T; Schwartz AG; Bocklage TJ; Belinsky SA
    Cancer Res; 2003 Aug; 63(16):4842-8. PubMed ID: 12941804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum.
    Gilliland FD; Harms HJ; Crowell RE; Li YF; Willink R; Belinsky SA
    Cancer Res; 2002 Apr; 62(8):2248-52. PubMed ID: 11956078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of the p16 gene by hypermethylation and loss of heterozygosity in adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Amatya VJ; Furonaka O; Tagawa K; Kohno N; Inai K
    Pathol Int; 2004 Jul; 54(7):486-9. PubMed ID: 15189501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung.
    Kim YT; Park SJ; Lee SH; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1378. PubMed ID: 16256792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
    Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
    Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer.
    Wolf P; Hu YC; Doffek K; Sidransky D; Ahrendt SA
    Cancer Res; 2001 Nov; 61(22):8113-7. PubMed ID: 11719438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
    Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
    Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas.
    Alves MK; Lima VP; Ferrasi AC; Rodrigues MA; De Moura Campos Pardini MI; Rabenhorst SH
    APMIS; 2010 Apr; 118(4):297-307. PubMed ID: 20402675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
    Schildhaus HU; Kröckel I; Lippert H; Malfertheiner P; Roessner A; Schneider-Stock R
    Int J Oncol; 2005 Jun; 26(6):1493-500. PubMed ID: 15870861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile.
    Guzman LM; Koriyama C; Akiba S; Eizuru Y; Castillo D; Corvalan A; Aguayo FR
    Biol Res; 2007; 40(3):365-72. PubMed ID: 18449464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A promoter methylation in gastric adenocarcinomas: clinical variables.
    Vo QN; Geradts J; Boudreau DA; Bravo JC; Schneider BG
    Hum Pathol; 2002 Dec; 33(12):1200-4. PubMed ID: 12514789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications.
    González-Quevedo R; García-Aranda C; Morán A; De Juan C; Sánchez-Pernaute A; Torres A; Díaz-Rubio E; Balibrea JL; Benito M; Iniesta P
    Int J Oncol; 2004 Feb; 24(2):349-55. PubMed ID: 14719111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma.
    Hsu HS; Chen TP; Hung CH; Wen CK; Lin RK; Lee HC; Wang YC
    Cancer; 2007 Nov; 110(9):2019-26. PubMed ID: 17876837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.